PhD positions (f/m/x) - Edited CAR-T cells

Your future with us
We are one of the leading university hospitals in Germany and network research, teaching and health care at the highest level. That's why many things are a lot bigger for us: the spectrum of exciting development opportunities. The limitless openness with which specialists from all over the world work together here. Or our commitment as an employer to support all employees as best we can in reconciling their job with their goals and life situations.
This is the University Hospital of Cologne: Everything but ordinary.

Your future in detail
The Translational Immuno-Oncology department (chair Prof. Dr. Renata Stripecke) at the Internal Medicine I (Director Prof. Michael Hallek) of the Cologne University Hospital Cologne develops immunotherapies against cancer. We are engineering chimeric antigen receptor T cells (CAR T cells) that kill lymphoma cells and cells infected with Epstein-Barr Virus (EBV). The CRISPR / Cas9 gene editing technique is currently being used to make CAR T cells more effective, safer and more widely available for patients. These gene-edited CAR T cells will be tested pre-clinically in vitro and in vivo. The clinical development of CAR-T cells against lymphomas will follow as a cooperation with several clinicians at the UKK and the University of Dresden.

PhD positions (f/m/x) - Edited CAR-T cells

Activities and responsibilities

Qualification profile

We offer